Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372567 · ClinicalTrials.gov registry record · Phase 3
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT00372567 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 69 participants.
The verdict
NCT00372567, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year.
Interventions
- DRUG imatinib mesylate
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372567
The ClinicalTrials.gov registry entry for NCT00372567 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00372567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372567 about?
NCT00372567 is a clinical study titled "Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors". A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sun...
What is the current status of trial NCT00372567?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2007-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00372567?
The interventions under investigation include: imatinib mesylate (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00372567?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.